Ackman seeks court ruling on Allergan special meeting

William Ackman's Pershing Square Capital Management said it had filed a lawsuit seeking confirmation that a requested special shareholder meeting of Allergan Inc's shareholders would not trigger Allergan's poison pill takeover defence.

_0">

The Botox maker has rejected a $53 billion joint offer from Ackman and Canadian drugmaker Valeant Pharmaceuticals International .

Allergan said in April that its board had adopted a one-year shareholder rights plan to give it more time to consider takeover proposals.

Allergan's shareholder rights plan will trigger if a person or group acquires 10 percent or more of its shares.

The lawsuit filed in Delaware Court of Chancery followed a request to Allergan from Pershing Square on June 6 seeking confirmation that Allergan would not use its poison pill to impede Ackman's request for a special meeting.

A response from Allergan's counsel on Thursday did not provide that confirmation, Pershing Square said.

Allergan rejected a sweetened offer from Valeant and the activist investor on Tuesday. (Reporting by Natalie Grover and Sweta Singh; Editing by Ted Kerr)

Popular posts from this blog

Model Stella Tennant dies 'suddenly' aged 50 as her family pay tribute to 'wonderful woman and an inspiration to us all'

ALL ABOUT CAR INSURANCE:

Video shows cracks in Champlain Towers a YEAR before Surfside condo collapsed: Prospective buyer says she didn't buy a condo there after seeing flaws in parking garage - as death toll rises to 78